Status:
COMPLETED
An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this observational study is to investigate the safety and efficacy of insulin detemir as add-on therapy in type 2 diabetic patients who are using oral antid...
Eligibility Criteria
Inclusion
- After the physician decision has been made to use insulin detemir therapy, any subject with Type 2 diabetes who is treated with any one or more of the oral antidiabetic drug (metformin, SU, repaglinide, TZDs) is eligible for the study. The selection of the subjects will be at the discretion of the individual physician. Particular attention should be paid to the drug interactions that are listed within the product label
Exclusion
- Subjects currently being treated with insulin detemir or any other insulin regimen including regular(bolus) insulin
- Subjects with a hypersensitivity to insulin detemir or to any of the excipients
- Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months. Women of childbearing potential who are not using adequate contraceptive methods
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
2155 Patients enrolled
Trial Details
Trial ID
NCT00842192
Start Date
April 1 2009
End Date
August 1 2010
Last Update
December 7 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Kfar Saba, Israel, 44425
2
Novo Nordisk Investigational Site
Amman, Jordan, 11844
3
Novo Nordisk Investigational Site
Amman, Lebanon, 11844
4
Novo Nordisk Investigational Site
Karachi, Pakistan